To test the safety and efficacy of Empagliflozin compared to a placebo in patients with chronic heart failure.
Principal Investigator: Marcus McKenzie, MD
Locations: Legacy Heart Center Plano, Congestive Heart Failure Center Plano, The Heart Group Plano, and The Heart Group McKinney
Sponsor: Boehringer Ingelheim
IRB Number: 017-067
Trial Status: Enrolling
Exclusions: Adults only
Change in Care: Participating will change your care
A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).
Get Detailed Information On Clinicaltrials.gov »
Physicians are members of the medical staff at one of Baylor Scott & White Health's subsidiary, community or affiliated medical centers and are neither employees nor agents of those medical centers, Baylor Scott & White The Heart Hospital – Plano or Baylor Scott & White Health.